SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences - Quaterly Results

17 May 2024 Evaluate
A decent increase of about 29.20% in the sales to Rs. 33324.00 millions was observed for the quarter ended March 2024. The sales figure stood at Rs. 25793.00 millions during the year-ago period.The company almost doubled its revenue to Rs. 14052.00 millions  from Rs. 4907.00 millions in the quarter ended March 2024.The company reported a good operating profit of 19303.00 millions compared to 10237.00 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 33324.00 25793.00 29.20 108187.00 87316.00 23.90 108187.00 87316.00 23.90
Other Income 3688.00 2512.00 46.82 11595.00 8219.00 41.08 11595.00 8219.00 41.08
PBIDT 19303.00 10237.00 88.56 51435.00 30028.00 71.29 51435.00 30028.00 71.29
Interest 1062.00 850.00 24.94 3907.00 2782.00 40.44 3907.00 2782.00 40.44
PBDT 18155.00 7349.00 147.04 47442.00 25208.00 88.20 47442.00 25208.00 88.20
Depreciation 1306.00 1199.00 8.92 5044.00 4886.00 3.23 5044.00 4886.00 3.23
PBT 16849.00 6150.00 173.97 42398.00 20322.00 108.63 42398.00 20322.00 108.63
TAX 2797.00 1243.00 125.02 7983.00 5030.00 58.71 7983.00 5030.00 58.71
Deferred Tax -1278.00 -53.00 2311.32 -1360.00 412.00 -430.10 -1360.00 412.00 -430.10
PAT 14052.00 4907.00 186.37 34415.00 15292.00 125.05 34415.00 15292.00 125.05
Equity 1006.00 1012.00 -0.59 1006.00 1012.00 -0.59 1006.00 1012.00 -0.59
PBIDTM(%) 57.93 39.69 45.95 47.54 34.39 38.25 47.54 34.39 38.25

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×